drugset
Drugs / Activated CIK
last change Jan 2021 re-read 2 minutes ago

Activated CIK

Cell therapy

Developed for
liver cancer · breast cancer · digestive system carcinoma · gastric cancer · kidney cancer · lung cancer
Investigated by
Beijing 302 Hospital · Benhealth Biopharmaceutical (Shenzhen) Co., Ltd.

Trials 1 · a red edge is where a trial was stopped

today NCT03146637 · Ph 2
201820192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT03146637 May 2017 → Jan 2021 liver cancer Benhealth Biopharmaceutical (Shenzhen) Co., Ltd. Unknown No outcome recorded
Also used as a comparator or background therapy in 6 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 26 trials
Phase 2 NCT03524261 Comparator May 2019 → Apr 2020 breast cancer Fuda Cancer Hospital, Guangzhou Withdrawn No outcome recorded
Phase 2 NCT03509298 Comparator Apr 2018 → May 2020 digestive system carcinoma Fuda Cancer Hospital, Guangzhou Withdrawn No outcome recorded
Phase 2 NCT03540199 Comparator Apr 2018 → May 2020 kidney cancer Fuda Cancer Hospital, Guangzhou Withdrawn No outcome recorded
Phase 2 NCT03554395 Comparator Apr 2018 → May 2020 gastric cancer Fuda Cancer Hospital, Guangzhou Withdrawn No outcome recorded
Phase 2 NCT03501056 Comparator Mar 2018 → May 2020 lung cancer Fuda Cancer Hospital, Guangzhou Withdrawn No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as activated CIK ClinicalTrials.gov intervention name — accepted as the source's own label NCT03484962 ↗
6

NCT03540199 ↗

NCT03501056 ↗

NCT03146637 ↗

NCT03554395 ↗

NCT03509298 ↗

NCT03524261 ↗
Modality Cell therapy “CIK cells were activated by bispecific antibody of anti-CD3-MUC1/CEA/EpCAM/GPC3” NCT03146637 ↗